Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs
Identifieur interne : 002106 ( Main/Exploration ); précédent : 002105; suivant : 002107Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs
Auteurs : O. Kayser [Allemagne] ; C. Olbrich [Allemagne] ; S. L. Croft [Royaume-Uni] ; A. F. Kiderlen [Allemagne]Source :
- Parasitology Research [ 0932-0113 ] ; 2003-06-01.
Abstract
Abstract.: The development of really new antiparasitic drugs to market level is a very rare event. A large number of lead structures have already been screened and discarded, the market is large but poor, and the administrative barriers are increasingly high and costly. Novel antiparasitics must not only be better, they must also be substantially safer than the existing repertoire. There are two major aspects to drug development. One is the strategy of pathogen-specific biochemical intervention, the other the strategy of optimal formulation and application. This review focuses on the latter. In finding and adapting innovative and "intelligent", i.e. parasite- and disease-specific formulations and delivery systems, established but deficient drugs might be optimised, enhancing their efficiency and reducing negative side effects at relatively low cost. Further, many promising new ideas are severely hampered by the low water solubility of the antiparasitic drug. Here as well, some of the innovative drug formulation and delivery systems discussed below might offer highly efficient, while technologically simple, solutions.
Url:
DOI: 10.1007/s00436-002-0769-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001609
- to stream Istex, to step Curation: 001609
- to stream Istex, to step Checkpoint: 000F42
- to stream Main, to step Merge: 002125
- to stream Main, to step Curation: 002106
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs</title><author><name sortKey="Kayser, O" sort="Kayser, O" uniqKey="Kayser O" first="O." last="Kayser">O. Kayser</name></author><author><name sortKey="Olbrich, C" sort="Olbrich, C" uniqKey="Olbrich C" first="C." last="Olbrich">C. Olbrich</name></author><author><name sortKey="Croft, S L" sort="Croft, S L" uniqKey="Croft S" first="S. L." last="Croft">S. L. Croft</name></author><author><name sortKey="Kiderlen, A F" sort="Kiderlen, A F" uniqKey="Kiderlen A" first="A. F." last="Kiderlen">A. F. Kiderlen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7E8246D40EDF9C8CDE7503EADD883F87BADD991F</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1007/s00436-002-0769-2</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-1S86R6XZ-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001609</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001609</idno><idno type="wicri:Area/Istex/Curation">001609</idno><idno type="wicri:Area/Istex/Checkpoint">000F42</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F42</idno><idno type="wicri:doubleKey">0932-0113:2003:Kayser O:formulation:and:biopharmaceutical</idno><idno type="wicri:Area/Main/Merge">002125</idno><idno type="wicri:Area/Main/Curation">002106</idno><idno type="wicri:Area/Main/Exploration">002106</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs</title><author><name sortKey="Kayser, O" sort="Kayser, O" uniqKey="Kayser O" first="O." last="Kayser">O. Kayser</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Freie Universität Berlin, Institut für Pharmazie, Pharmazeutische Technologie, Biopharmazie und Biotechnologie, Kelchstrasse 31, 12169 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Olbrich, C" sort="Olbrich, C" uniqKey="Olbrich C" first="C." last="Olbrich">C. Olbrich</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Schering Deutschland GmbH, Müllerstrasse 173, 13356 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Croft, S L" sort="Croft, S L" uniqKey="Croft S" first="S. L." last="Croft">S. L. Croft</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Kiderlen, A F" sort="Kiderlen, A F" uniqKey="Kiderlen A" first="A. F." last="Kiderlen">A. F. Kiderlen</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Robert Koch-Institut, Nordufer 20, 13353 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Parasitology Research</title><title level="j" type="abbrev">Parasitol Res</title><idno type="ISSN">0932-0113</idno><idno type="eISSN">1432-1955</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2003-06-01">2003-06-01</date><biblScope unit="volume">90</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S63">S63</biblScope><biblScope unit="page" to="S70">S70</biblScope></imprint><idno type="ISSN">0932-0113</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0932-0113</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract.: The development of really new antiparasitic drugs to market level is a very rare event. A large number of lead structures have already been screened and discarded, the market is large but poor, and the administrative barriers are increasingly high and costly. Novel antiparasitics must not only be better, they must also be substantially safer than the existing repertoire. There are two major aspects to drug development. One is the strategy of pathogen-specific biochemical intervention, the other the strategy of optimal formulation and application. This review focuses on the latter. In finding and adapting innovative and "intelligent", i.e. parasite- and disease-specific formulations and delivery systems, established but deficient drugs might be optimised, enhancing their efficiency and reducing negative side effects at relatively low cost. Further, many promising new ideas are severely hampered by the low water solubility of the antiparasitic drug. Here as well, some of the innovative drug formulation and delivery systems discussed below might offer highly efficient, while technologically simple, solutions.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Berlin</li><li>Grand Londres</li></region><settlement><li>Berlin</li><li>Londres</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Kayser, O" sort="Kayser, O" uniqKey="Kayser O" first="O." last="Kayser">O. Kayser</name></region><name sortKey="Kayser, O" sort="Kayser, O" uniqKey="Kayser O" first="O." last="Kayser">O. Kayser</name><name sortKey="Kiderlen, A F" sort="Kiderlen, A F" uniqKey="Kiderlen A" first="A. F." last="Kiderlen">A. F. Kiderlen</name><name sortKey="Olbrich, C" sort="Olbrich, C" uniqKey="Olbrich C" first="C." last="Olbrich">C. Olbrich</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Croft, S L" sort="Croft, S L" uniqKey="Croft S" first="S. L." last="Croft">S. L. Croft</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002106 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002106 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7E8246D40EDF9C8CDE7503EADD883F87BADD991F
|texte= Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs
}}
| This area was generated with Dilib version V0.6.33. |  |